Interleukin-1β and Arrhythmogenic Cardiomyopathy
Author Information
Author(s): Penna Vinay R., Amrute Junedh M., Engel Morgan, Shiel Emily A., Farra Waleed, Cannon Elisa N., Leu-Turner Colleen, Ma Pan, Villanueva Ana, Shin Haewon, Parvathaneni Alekhya, Jager Joanna, Bueno-Beti Carlos, Asimaki Angeliki, Lavine Kory J., Saffitz Jeffrey E., Chelko Stephen P.
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
Can targeting IL-1β improve outcomes in patients with arrhythmogenic cardiomyopathy?
Conclusion
Targeting IL-1β may improve cardiac function and reduce fibrosis in arrhythmogenic cardiomyopathy.
Supporting Evidence
- The study identified disease-associated spatial niches in myocardial samples from patients with ACM.
- Increased levels of IL-1β were found in inflammatory macrophage subsets in ACM samples.
- Treatment with an anti-IL-1β neutralizing antibody in mice showed improved cardiac function.
Takeaway
This study found that a protein called IL-1β is linked to heart problems in a specific disease, and blocking it might help people feel better.
Methodology
Single nucleus RNA sequencing and spatial transcriptomics were performed on myocardial samples from patients with ACM and control donors.
Participant Demographics
Patients with arrhythmogenic cardiomyopathy and control donors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website